Related Experiment Videos
O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors
S Hongeng1, T P Brent, R A Sanford
1Departments of Hematology-Oncology, Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Abstract:
Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.
Insights
Chloroethylnitrosoureas (CENUs) treat CNS tumors by alkylating DNA. O6-methylguanine-DNA methyltransferase (MGMT) repairs this, potentially causing resistance. This study quantifies MGMT in pediatric CNS tumors, guiding CENU treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chloroethylnitrosoureas (CENUs) are vital in treating central nervous system (CNS) tumors.
- Tumor resistance to CENUs may stem from the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT).
- MGMT repairs O6-alkylguanine DNA lesions, a proposed mechanism for CENU's antitumor activity.
Purpose of the Study:
- To quantify MGMT levels in newly diagnosed pediatric CNS tumors.
- To compare biochemical and Western immunoblot assays for MGMT quantitation.
- To correlate MGMT levels with specific pediatric CNS tumor types.
Main Methods:
- Biochemical assays for MGMT activity.
- Western immunoblot assays for MGMT protein levels.
- Analysis of MGMT levels in a cohort of pediatric CNS tumors.
Main Results:
- A strong correlation (r = 0.66) was observed between biochemical and Western immunoblot methods for MGMT quantitation.
- Medulloblastoma/primitive neuroectodermal tumor and ependymoma exhibited the highest MGMT levels.
- High-grade gliomas showed lower MGMT levels than medulloblastoma/ependymoma, followed by low-grade gliomas.
Conclusions:
- MGMT levels vary significantly across different pediatric CNS tumor types.
- These findings support the role of MGMT in CENU resistance in pediatric CNS tumors.
- Quantifying MGMT may inform the clinical use of CENUs in pediatric CNS oncology.